THE PRODUCTION by human tumours of a variety of substances, widely known today as "tumour markers", is now well recognized and could, at least in theory, provide a biochemical index to facilitate cancer detection and treatment. Unfortunately, no tumour marker has yet been found which is specific for malignant disease, and their value is minimal in the detection and differential diagnosis of primary localized cancers (Neville & Cooper, 1976) . However, some markers have proved to be of value as aids in the detection of metastases and therapy monitoring. The best examples are o-foetoprotein (AFP) and germ-cell tumours and hepatomas, the carcinoembryonic antigen (CEA) and colorectal carcinomas, human chorionic gonadotrophin (hCG) and choriocarcinoma and a variety of hormones in association with the appropriate endocrine tumours (Laurence & Neville, 1981) .
Tumour markers for breast cancer have been the subject of considerable research, and many claims have been made for at least 40 different markers in this disease. At present, the best markers appear to be the plasma levels of CEA, alkaline phosphatase and y-glutamyl transpeptidase (Coombes et al., 1 980a, b) but even these are of little clinical relevance to the earlier detection of primary and/or metastatic disease.
Human placental lactogen (hPL) and pregnancy-specific 3i-glycoprotein (SP1) are placental proteins normally present in the sera of pregnant women. Their "ectopic" secretion by breast tumours has been claimed. hPL has been found in the sera of breast-cancer patients (Gaspard et al., 1973; Sheth et al., 1977) and in breast-carcinoma tissue (Horne et al., 1976) while SP1 has been detected in sera (Searle et al., 1978; Wiirz, 1979; Grudzinskas et al., 1980; Bremner et al., 1981) , breast-tumour tissue (Horne et al., 1976; Wurz, 1979; Inaba et al., 1980; Bremner et al., 1981) and in the culture medium in which a breast-cancer cell line has been grown (Horne et al., 1979) . Perhaps the most potentially important study has been that of Horne et al. (1976) 24 h, after which the anti-rabbit-yglobulin was added and the tubes were incubated for a fuirther 24 h. The sensitivity limit of the assay was 0-2 pug/l.
The intra-assay and the inter-assay coefficients of variation wxNere 87%o and 1220/, respectively. SP, readioimn maunoassay. Estinmations of SP, were performed using a polyethylene glycol precipitation radioimmunoassay described elsewhere (Grudzinskas et al., 1977) . The minimuim detection limit was 20 ,tg/l. The intra-assay andI the interassav coefficients of variation were 400 and 90o, respectively. In both assays standards and samples were run in triplicate.
Estimations of hPL were performed in all 262 patients. SPi was measured in in only 193 patients: 99 of the local/ regional group, 5 of the locally recurrent group and 89 of the disseminated group.
No patient, had an hPL or a SP1 level above the sensitivitv limits of the resp)ective assayvs.
There is a contiinuing need to derive markers demonstrable in breast tumours or in the sera of breast-cancer patients wNhich may give a gutide as to future prog-h1L'f ANI) SP1 IN BREAST-CANCER SERUM2 inosis as well as providing indices to monitor the course of the disease. The demonstration of placental protein in breast tumours by Horne et al. (1976) appeared to be of importance. Our study, however, has failed to detect raised levels in the blood of breast cancer patients. Doubts, therefore, about the prognostic value of such pregnancy proteins in breast cancer must noNw be expressed.
The evidence reported by Gaspard et al. (1973) and Horne et ai. (1976) to support hPL production by breast tumours has been based on different methods from that used in the present work. The most directly relevant study to our own has been reported by Sheth et al. (1977) who used a less sensitive double-antibody radioimmunoassay (1-2 pg/l). They foundl slightly raised levels in the 3-5 jug/l range. However, there was nio correlation between the raised levels and any clinical or pathological parameters. The sensitivity of the present hPL radioimmunoassay is similar to that of Weintraub & Rosen (1971) . They studied sera from 295 patients with a variety of non-trophoblast malignant tumours, and raised hPL values were found in only a minority of patients. In a personal communication, Rosen (1979) has confirmed that he never found raised serum hPL in patients with breast cancer. (Searle et al., 1978 : Wurz, 1979 Grudzinskas et al., 1980 : Bremner et al., 1981 (Searle et al., 1978 : Wiirz, 1979 : Grudzinskas et al., 1980 Bremner et al., 1981 Conflicting results have been found in patients with breast carcinoma as to the nature of the circulating material when tested for parallelism with reference preparations. Wurz (1979) Whilst the presence of SP1 was deinionstrated in the medium in which a breast cancer cell line has been grown (Horne et al., 1979) other workers have found that fibroblast cell lines in culture also produce immunoreactive SP1 (Rosen et al., Unpub.; Engvall et al., Unpub.) . Nevertheless the study of localization of SP1 by immunocytochemistry by Inaba et al. (1980) compares favourably with that by [lorne et al. (1976) : 526°/ and 600%, respectively.
Further studies are required to determine whether SP1 is truly being assayed and the significance of the "SP, raised levels" detected in patients with breast cancer iusing antisera capable of discriminating between the various forms of this protein (Teisner et al., 1978; Towler et al., 1978) .
MIeanwhile it seems clear that the measurement of circulating hPL and SP1 is of no clinical use in the management of breast cancer patients.
